D. Boral Capital Reiterates “Buy” Rating for Citius Pharmaceuticals (NASDAQ:CTXR)

Citius Pharmaceuticals (NASDAQ:CTXR)‘s stock had its “buy” rating reaffirmed by research analysts at D. Boral Capital in a research note issued on Wednesday,Benzinga reports. They presently have a $6.00 target price on the stock.

Other analysts also recently issued reports about the company. Wall Street Zen upgraded Citius Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research report on Saturday, December 27th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Citius Pharmaceuticals in a research report on Monday, December 29th. One analyst has rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus target price of $6.00.

Citius Pharmaceuticals Price Performance

Shares of NASDAQ CTXR opened at $0.87 on Wednesday. The business’s 50 day moving average is $0.81 and its two-hundred day moving average is $1.09. Citius Pharmaceuticals has a 1-year low of $0.63 and a 1-year high of $2.48. The stock has a market capitalization of $19.41 million, a P/E ratio of -0.35 and a beta of 1.51.

Citius Pharmaceuticals (NASDAQ:CTXR) last posted its quarterly earnings data on Friday, February 13th. The company reported ($0.38) earnings per share (EPS) for the quarter. As a group, equities research analysts anticipate that Citius Pharmaceuticals will post -4.5 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Citius Pharmaceuticals

Several hedge funds have recently bought and sold shares of CTXR. XTX Topco Ltd bought a new stake in shares of Citius Pharmaceuticals during the second quarter worth $32,000. NewEdge Advisors LLC purchased a new position in Citius Pharmaceuticals in the 2nd quarter worth about $40,000. Asset Advisory Group Inc. purchased a new position in Citius Pharmaceuticals in the 4th quarter worth about $46,000. Finally, Heights Capital Management Inc. bought a new stake in Citius Pharmaceuticals during the 4th quarter valued at about $622,000. Institutional investors own 16.88% of the company’s stock.

Citius Pharmaceuticals Company Profile

Citius Pharmaceuticals is a clinical‐stage specialty pharmaceutical company focused on the development and commercialization of critical care products and novel drug delivery systems. Headquartered in Cranford, New Jersey, the company aims to address unmet medical needs in acute care, hospital‐acquired infections and subcutaneous delivery of biologics. Citius operates as a Delaware corporation and trades on the NASDAQ under the symbol CTXR.

One of the company’s leading assets is Mino-Lok, an antibiotic lock solution designed to treat catheter‐related bloodstream infections without catheter removal.